Related Experiment Video
Updated: Feb 10, 2026

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control
Yan Li1,2,3, Sungjin Chung1,2, Zhilian Li1,2
1Division of Nephrology and Hypertension, Department of Medicine, and.
Abstract:
Extensive kidney fibrosis occurs in several types of chronic kidney diseases. PBI-4050, a potentially novel first-in-class orally active low-molecular weight compound, has antifibrotic and antiinflammatory properties. We examined whether PBI-4050 affected the progression of diabetic nephropathy (DN) in a mouse model of accelerated type 2 diabetes and in a model of selective tubulointerstitial fibrosis. eNOS-/- db/db mice were treated with PBI-4050 from 8-20 weeks of age (early treatment) or from 16-24 weeks of age (late treatment). PBI-4050 treatment ameliorated the fasting hyperglycemia and abnormal glucose tolerance tests seen in vehicle-treated mice. In addition, PBI-4050 preserved (early treatment) or restored (late treatment) blood insulin levels and increased autophagy in islets. PBI-4050 treatment led to significant improvements in lifespan in the diabetic mice. Both early and late PBI-4050 treatment protected against progression of DN, as indicated by reduced histological glomerular injury and albuminuria, slow decline of glomerular filtration rate, and loss of podocytes. PBI-4050 inhibited kidney macrophage infiltration, oxidative stress, and TGF-β-mediated fibrotic signaling pathways, and it also protected against the development of tubulointerstitial fibrosis. To confirm a direct antiinflammatory/antifibrotic effect in the kidney, further studies with a nondiabetic model of EGFR-mediated proximal tubule activation confirmed that PBI-4050 dramatically decreased the development of the associated tubulointerstitial injury and macrophage infiltration. These studies suggest that PBI-4050 attenuates development of DN in type 2 diabetes through improvement of glycemic control and inhibition of renal TGF-β-mediated fibrotic pathways, in association with decreases in macrophage infiltration and oxidative stress.
Insights
PBI-4050, an antifibrotic compound, improved glycemic control and extended lifespan in diabetic mice. It also protected against diabetic nephropathy by reducing kidney fibrosis, inflammation, and oxidative stress.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy (DN) is a major complication of diabetes, characterized by progressive kidney fibrosis.
- Existing treatments for DN have limitations in halting disease progression.
- PBI-4050 is an orally active compound with demonstrated antifibrotic and anti-inflammatory properties.
Purpose of the Study:
- To investigate the efficacy of PBI-4050 in ameliorating diabetic nephropathy in a mouse model.
- To assess the impact of PBI-4050 on glycemic control, kidney fibrosis, and inflammation in diabetic mice.
- To evaluate the antifibrotic and anti-inflammatory effects of PBI-4050 in a non-diabetic model of kidney injury.
Main Methods:
- Treatment of eNOS-/- db/db mice with PBI-4050 during early (8-20 weeks) or late (16-24 weeks) stages of diabetes.
- Assessment of glycemic parameters, insulin levels, islet autophagy, and lifespan.
- Histological evaluation of kidney injury, albuminuria, glomerular filtration rate, and podocyte loss.
- Analysis of kidney macrophage infiltration, oxidative stress, and TGF-β signaling pathways.
- Studies in a non-diabetic model of EGFR-mediated tubulointerstitial injury.
Main Results:
- PBI-4050 improved fasting hyperglycemia, glucose tolerance, and insulin levels, while increasing islet autophagy.
- Significant improvements in lifespan were observed in PBI-4050 treated diabetic mice.
- PBI-4050 treatment reduced glomerular injury, albuminuria, GFR decline, and podocyte loss.
- The compound inhibited kidney macrophage infiltration, oxidative stress, and TGF-β-mediated fibrosis.
- PBI-4050 demonstrated direct anti-inflammatory and antifibrotic effects in a non-diabetic kidney injury model.
Conclusions:
- PBI-4050 effectively attenuates the progression of diabetic nephropathy in type 2 diabetes.
- The therapeutic benefits are attributed to improved glycemic control and direct inhibition of renal fibrotic pathways.
- PBI-4050 shows promise as a novel treatment for diabetic kidney disease by reducing inflammation and oxidative stress.
Related Concept Videos
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Feedback Inhibition
Kidney Structure
Internal Receptors
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Receptor-mediated Endocytosis

